Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

Creative Commons License

Dalva-Aydemir S., Bajpai R., Martinez M., Adekola K. U. A., Kandela I., Wei C., ...Daha Fazla

CLINICAL CANCER RESEARCH, cilt.21, sa.5, ss.1161-1171, 2015 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 5
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1158/1078-0432.ccr-14-1088
  • Dergi Adı: CLINICAL CANCER RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1161-1171
  • Ankara Üniversitesi Adresli: Hayır

Özet

Purpose: We have previously demonstrated that ritonavir targeting of glycolysis is growth inhibitory and cytotoxic in a subset of multiple myeloma cells. In this study, our objective was to investigate themetabolic basis of resistance to ritonavir and to determine the utility of cotreatment with the mitochondrial complex I inhibitor metformin to target compensatory metabolism.